REPLIGEN CORP Payments for Restructuring
REPLIGEN CORP (RGEN) reported Payments for Restructuring of $1.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-07-29
- REPLIGEN CORP payments for restructuring for the quarter ending 2026-06-30 was $1.02M, a 243.43% increase year-over-year.
- REPLIGEN CORP payments for restructuring for the quarter ending 2026-03-31 was $399.00K, a 33.83% decline year-over-year.
- REPLIGEN CORP payments for restructuring for the quarter ending 2025-12-31 was $0.00.
- REPLIGEN CORP payments for restructuring for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- REPLIGEN CORP payments for restructuring for fiscal 2025 was $900.00K.
- REPLIGEN CORP payments for restructuring for fiscal 2023 was $4.11M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $1.42M 10-Q · filed 2026-07-29 | $1.42M derived: sum of 3 quarters · filed 2026-07-29 | $1.42M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $399.00K 10-Q · filed 2026-05-06 | $399.00K derived: sum of 2 quarters · filed 2026-05-06 | $399.00K derived: sum of 3 quarters · filed 2026-05-06 | $696.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $297.00K derived: sum of 3 quarters · filed 2026-02-26 | $900.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $297.00K derived: sum of 2 quarters · filed 2025-11-04 | $900.00K 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $297.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $900.00K 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | $603.00K 10-Q · filed 2025-04-29 | |||
| 2024-09-30 | $3.62M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-18 | $5.23M derived: sum of 2 quarters · filed 2024-11-18 | $5.75M 10-Q · filed 2024-11-18 | $7.20M derived: sum of 4 quarters · filed 2024-11-18 |
| 2024-06-30 | $1.61M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $2.13M 10-Q/A · filed 2024-11-18 | $3.58M derived: sum of 3 quarters · filed 2024-11-18 | |
| 2024-03-31 | $519.00K 10-Q/A · filed 2024-11-18 | $1.98M derived: sum of 2 quarters · filed 2024-11-18 | ||
| 2023-12-31 | $1.46M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-11-18 | $4.11M 10-K/A · filed 2024-11-18 | ||
| 2023-09-30 | $2.65M 10-Q/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |